To Estimate the Prevalence of Peyronie’s Disease and to Study the Effectiveness of Intralesional Verapamil in Resolution of Plaque of Peyronie’s Disease

Abstract

Background: Peyronie’s disease is a connective tissue disorder, characterized by the formation of a fibrotic lesion or plaque in the tunica albuginea, which leads to penile deformity. The true prevalence of Peyronie’s disease is unknown. An evaluation of existing epidemiological data on Peyronie’s disease revealed a prevalence rate of 3.2%. Verapamil effectiveness is predicted on its ability to affect fibroblast function at multiple levels, including cell proliferation, extracellular matrix protein synthesis and secretion, and collagen breakdown. Calcium antagonists may thus have the potential to reduce, halt, or even reverse plaque formation and disease progression. Materials and Methods: A prospective study was conducted on patients who attended the Surgery Outpatient Department of R. M. L Medical College and Hospital, Lucknow, with the diagnosis of Peyronie’s disease in 2 years (2020–2022) with a sample size of 50 patients. Results: Intralesional verapamil injection therapy resulted in the reduction of pain in 88% of cases, reduction of plaque size in 75%–80% of cases, reduction of penile curvature in 70%–75% of cases, and improvement in erectile dysfunction in 50%–55% of cases. Conclusions: In our study , it was found that intralesional varapamil therapy causes significant reduction in pain during erection, penile curvature, plaque size and improvement in erectile dysfunction in Peyronie’s disease.

Keywords

• erectile dysfunction
• intralesional verapamil
• penile deformity